IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy

This study evaluates the anti-tumor mechanism of IMM47, a humanized anti-CD24 mAb. Biolayer interferometry, ELISA and flow cytometry methods were used to measure the IMM47 binding, affinity, ADCC, ADCP, ADCT and CDC activities. In vivo therapeutical efficacy was measured in transplanted mouse models...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Song, Chen, Dianze, Guo, Huiqin, Yang, Yanan, Liu, Dandan, Yang, Chunmei, Bai, Xing, Zhang, Wei, Zhang, Li, Zhao, Gui, Tu, Xiaoping, Peng, Liang, Liu, Sijin, Song, Yongping, Jiang, Zhongxing, Zhang, Ruliang, Yu, Jifeng, Tian, Wenzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576855/
https://www.ncbi.nlm.nih.gov/pubmed/37846296
http://dx.doi.org/10.1093/abt/tbad020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576855/
https://www.ncbi.nlm.nih.gov/pubmed/37846296
http://dx.doi.org/10.1093/abt/tbad020

Ejemplares similares